odesivimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiviral, monoclonal antibodies 5438 2135632-30-1

Description:

MoleculeDescription

Molfile

Synonyms:

  • odesivimab
  • odesivimab-ebgn
  • REGN3471
  • FG-102
Odesivimab in combination with maftivimab and atoltivimab has been approved as INMAZEB for the treatment of infection caused by Zaire ebolavirus. INMAZEB is a combination of the three recombinant human IgG1kappa monoclonal antibodies that inhibit Zaire ebolavirus, each targeting the Zaire ebolavirus glycoprotein (GP). Maftivimab is a neutralizing antibody that blocks entry of the virus into susceptible cells. Odesivimab is a non-neutralizing antibody that induces antibody-dependent effector function through FcgammaRIIIa signaling when bound to its target. Odesivimab also binds to the soluble form of Zaire ebolavirus glycoprotein (sGP). Atoltivimab combines both neutralization and FcgammaRIIIa signaling activities.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 14, 2020 FDA REGENERON PHARMACEUTICALS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Ebola virus disease indication 37109004 DOID:4325




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Low affinity immunoglobulin gamma Fc region receptor III-A Membrane receptor ANTIBODY BINDING EC50 8.80 DRUG LABEL DRUG LABEL
Envelope glycoprotein Glycoprotein ANTIBODY BINDING Kd 8.08 DRUG LABEL DRUG LABEL

External reference:

IDSource
D11921 KEGG_DRUG
UY9LQ8P6HW UNII
C5417454 UMLSCUI
CHEMBL4298188 ChEMBL_ID
DB15900 DRUGBANK_ID
018541 NDDF
1052218000 SNOMEDCT_US
2461340 RXNORM
C000711951 MESH_SUPPLEMENTAL_RECORD_UI
11033 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Inmazeb HUMAN PRESCRIPTION DRUG LABEL 3 61755-018 INJECTION, SOLUTION 241.70 mg INTRAVENOUS BLA 29 sections
Inmazeb HUMAN PRESCRIPTION DRUG LABEL 3 61755-018 INJECTION, SOLUTION 241.70 mg INTRAVENOUS BLA 29 sections
Inmazeb HUMAN PRESCRIPTION DRUG LABEL 3 61755-018 INJECTION, SOLUTION 241.70 mg INTRAVENOUS BLA 29 sections
Inmazeb HUMAN PRESCRIPTION DRUG LABEL 3 61755-019 INJECTION, SOLUTION 483.30 mg INTRAVENOUS BLA 29 sections
Inmazeb HUMAN PRESCRIPTION DRUG LABEL 3 61755-019 INJECTION, SOLUTION 483.30 mg INTRAVENOUS BLA 29 sections
Inmazeb HUMAN PRESCRIPTION DRUG LABEL 3 61755-019 INJECTION, SOLUTION 483.30 mg INTRAVENOUS BLA 29 sections